Aspire Private Capital’s VanEck Biotech ETF BBH Stock Holding History

Aspire Private Capital’s Portfolio BBH Stock Details BBH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-416	Closed	-$53K	–	528
2019 Q1	$53K	Hold	416	–	–	0.03%	227
2018 Q4	$46K	Buy	+416	New	+$50.3K	0.03%	219

Other funds holding BBH

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TIA

Traphagen Investment Advisors Oradell, New Jersey $1.4B AUM 19.32% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

MCM

Murphy Capital Management Bedminster, New Jersey $720M AUM 9.22% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

MJRIC

Mogy Joel R Investment Counsel Beverly Hills, California $1.75B AUM 17.81% 1-Year Est. Return

BRM

Boston Research & Management Manchester, Massachusetts $421M AUM 16.18% 1-Year Est. Return

Aspire Private Capital's BBH Position: Q2 2019 in Review

Aspire Private Capital sold out of VanEck Biotech ETF (BBH) in Q2 2019, closing a stake of 416 shares — an estimated $53K sold.

Aspire Private Capital first reported a position in BBH in Q4 2018 and held it in 2 quarters. The position peaked at $53K in Q1 2019. 84 funds tracked by Wall St. Rank hold BBH as of Q2 2019.

Aspire Private Capital reported no remaining VanEck Biotech ETF position as of Q2 2019 after selling out during the quarter.
Aspire Private Capital sold 416 VanEck Biotech ETF shares in Q2 2019, an estimated $53K.
Aspire Private Capital first reported a position in VanEck Biotech ETF in Q4 2018 and held it in 2 quarters.
Aspire Private Capital's VanEck Biotech ETF position peaked at $53K in Q1 2019.
84 funds tracked by Wall St. Rank held VanEck Biotech ETF as of Q2 2019.

Based on Aspire Private Capital's 13F filing for Q2 2019, filed 13 Aug 2019.